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Eleven years of chronic hemodialysis in Uruguay: Modality time
course. Uruguay is a developing country with 3.1 million inhabitants.
Chronic dialysis treatment (CDT) began to spread after the creation of the
National Fund of Resources (NFR) in 1980. This Fund receives contri-
bution from all inhabitants to finance, among others, the high cost
treatment, dialysis and renal transplantation (RT). We analyzed the data
base from 1981 to 1991 of the Hemodialysis National Registry to find the
mortality time course. To compare with other populations, indirect
standarization methods were used. Two thousand and seventy-one pa-
tients received chronic hemodialysis treatment (CHT) during the period
cited. Incidence and prevalence of end-stage renal disease (ESRD)
increased from 32 to 90 and from 38 to 390 patients per millon population,
respectively. Annual gross mortality decreased from 21 to 9% in spite of
a simultaneouse increase in the percentage of high risk patients. Accord-
ing to the age-matched national general mortality, the ratio between
observed and expected deaths was 21 in 1981 and 4 in 1991. The
standardized death rate was 142.8 deaths/1000 patient-years at risk when
the USA ESRD 1987 to 1989 mortality rate by age, race and diagnosis was
used as a standard. These results point out that it is possible to provide
ESRD treatment in developing Countries to achieve appropriate Compar-
ative results in delaying mortality.
Uruguay has a stable, predominantly white population around
3.1 million inhabitants, 10.7% of whom are older than 65 years
(census 1985) [1]. For 1990 the gross national product (GNP) per
person was U $2620 and the human development index 0.881 [2].
For the same year the annual mortality was 1%, the infant
mortality rate 21 per 1000 live births, and life expectancy was 72
years [3]. There were only sporadic cases of chronic dialysis
treatment (CDT) before 1981. CDT began to spread rapidly after
the creation by the Uruguayan government of the National Fund
of Resources (NFR) in 1980. The NFR supports the treatment by
hemodialysis (HD), chronic ambulatory peritoneal dialysis(CAPD) and renal transplantation (RT) for all persons with
end-stage renal disease (ESRD). The Uruguayan Society of
Nephrology has had a national registry since 1981. This registry
has accumulated data from the entire population from the start of
CDT in the country.
The goal of the present study was to describe mortality time
trends in Uruguayan chronic HD patients and compare it with
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other populations. The Uruguayan general population was used
as the age standard.
Recently, Wolfe et al [4] suggested that foreign countries could
compare their ESRD mortality rates to the USA rates using
adequate methodology. Therefore the USA ESRD 1987 to 1989
mortality by age, race and diagnosis was used as another standard
population for comparison.
Methods
Patients
All patients were included on the registry at the onset of chronic
hemodialysis treatment (CHT). Data were obtained yearly
through the collaboration of all physicians in charge of dialysis
units in the entire country. In this study the data base of the period
1981 to 1991 was considered.
At the end of the period (1991), there were 28 CHT centers and
80 nephrologists. Before 1985 all facilities were in the capital city,
Montevideo. By 1991 there were 10 centers spread over the rest of
the country. The general characteristic of CHT changed in
Uruguay during the interval [5]: before 1985, 80% of the centers
had no water treatments; in 1991 all had inverse osmosis or
deionizers. The weekly frequency of HD was thrice for 80% of the
patients before 1984, 85% between 1984 and 1986, and more than
90% of the patients after 1986. The duration of HD sessions was
four hours in most cases. Acetate dialysate and cuprophane
membranes were mainly used. Since 1981 all centers have reused
the dialyzers. Reuse increased progressively; in 1991 the mean was
seven hemodiayses per dialyzer. In 1990 erythropoietin was used
for the first time in Uruguay, and during this year 20 ESRD
patients were treated with the drug.
During the period of 1981 to 1991, 2071 ESRD patients were
hemodialyzed (2036 whites and 35 blacks). Forty-one patients
were admitted before January 1, 1981. Seven hundred and
seventeen patients died and 179 received a RT. Twenty-six
patients were transferred to DPCA due to difficulties with the
vascular access for HD. Eight patients transferred to other
countries for personal reasons and were lost to follow-up.
The population data to calculate the incidence and prevalence
of ESRD was taken from the 1985 National Census [1].
The annual gross mortality rate (GMR) was calculated as the
number of deaths divided by one half the number of those who
were alive on January 1 plus one half the number alive on
December 31 of each year. The death rate was computed as the
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Table 1. Chronic hemodialysis in Uruguay (1981 to 1991)
New patients
Deaths GM
Deaths/1000
patient-yearsYear N Diabetes Age > 65
1981 95 5 5 15 21 235
1982 125 18 9 29 19 192
1983 161 21 29 43 17 174
1984 164 23 34 59 17 175
1985 182 26 48 63 14 145
1986 160 22 32 67 13 126
1987 181 32 49 74 12 126
1988 224 38 72 76 11 113
1989 247 31 73 84 10 104
1990 225 27 72 107 12 118
1991 266 39 70 95 9 88
Number of new patients, number of diabetics and those aged more than
65 years (>65) among new patients, number of deaths, gross mortality
percentage (GM), and deaths/1000 patient-years at risk. A total of 717
patients died during the period of 1981 to 1991. Among them, it was
impossible to know the precise year of death of five patients, and this is the
reason for not including them in this Table.
total number of deaths per 1000 patient-years at risk by determin-
ing the exact time at risk for each patient. The survival curve was
drawn using the Kaplan-Meier method.
The indirect standardization method was used to adjust the
mortality results [6]. The basis for such analysis is the ratio of the
observed to the expected number of deaths: the standardized
mortality ratio (SMR). The standardized death rate (SDR) in the
study population was computed multiplying the overall death rate
in the standard population by SMR.
Two standard populations were used: (1) the annual mortality
by age in the Uruguayan general population, according the 1985
census data and the official report of the government [7]. The
SMR was called SMR1. (2) The ESRD USA death rates during
1987 to 1989 per 1000 patient-years at risk [41 was used as the age,
primary disease and race standard. The SMR was called SMR2
and the corresponding standardized death rate, SDR2. In each
year the start date for a patient was January 1 and the stop date
was one of the following: the last day of the year (December 31),
the date of death, the date of RT, or the last day of follow-up,
whichever occurred first. For this analysis we adhered to the
inclusion and follow-up criteria described by Wolfe et al [4]:
patients with a prior failed RT and patients who recovered renal
function during follow-up were excluded from analysis. Patients
who were transferred to other facilities were followed with regard
to RT and mortality status until the study stop date. Only patients
who started therapy more than 90 days before the study start date
were included. Only those days of patient follow-up after the start
date were included in the computations. Due to this inclusion and
follow-up criteria, the number of patients considered in this
analysis was 1665, of whom 574 died.
Results
Demographic details and mortality of the Uruguayan chronic
HD population is sumarized in Table 1. Figure 1 shows the time
course of incidence and prevalence. Figure 2 shows the probability
of survival for diabetic and non-diabetic patients.
Gross mortality decreased (Table 1) from 21 to 9%, despite the
large increase in high risk MD population rate (diabetics and
elders older than 65 years; Fig. 3).
SMR1 time course is independent of the age changes, so it
allows an approach to the true mortality time course (Fig. 4). It
decreased from 27 in 1981 to 4 in 1991. The overall SMR1 was 7.
The SMR2 was calculated as 574/1002 = 0.57, which indicates
that the number of deaths in the Uruguayan ESRD population
during the period considered was lower than the USA ESRD
norm. Thus, while the USA ESRD overall mortality was 250.6
deaths/1000 patient-years at risk, the SDR2 was 0.57*250.6 =
142.8. The P value from the chi-square statistic indicates that the
difference in rates is statistically significant. Figure 5 shows the
annual deaths/1000 patients at risk and SDR2 trend course.
Discussion
Dialysis is a high cost treatment anywhere in the world. The
worldwide mean cost of maintaining a patient in HD or CAPD is
around U $30,000 per year. This is greater than the GNP of the
world's wealthiest countries (U $18,000 to U $20,000 per person).
Third world countries have great difficulties in financing this type
of treatment [8]. During 1991 in Uruguay, the annual cost of HD
(U $13,300 per patient) represented about 4 times the 1991 per
capita GNP level (hospitalization and outpatient drugs not includ-
ed).
In Uruguay MD began in 1958 as a treatment protocol for acute
renal failure [9], and in 1965 was instituted as the treatment
regimen for ESRD [10]. Owing to the high cost, there were only
sporadic cases of CHT before the creation of the NFR. Since
1980, the NFR has received contributions from all inhabitants of
the country to finance, among others, the high cost of treatment,
dialysis and RT. Thanks to this organization and to a liberal
acceptance policy there was a rapid expansion of Cl-iT. The
incidence and prevalence (Fig. 1) were, in the last few years,
similar to the rates found in developed countries [11, 12]. The
yearly contribution to the NFR was about U $12 per inhabitant in
1991; forty percent were for CHT expenses.
DPCA had a limited development in Uruguay during the period
analyzed; only 48 patients were treated with this modality until
1991.
There has been a national program and an experienced clinical
group working in RT in Uruguay since 1981. The number of
cadaveric and living-related renal donors was low, which explains
the limited number of RT done during this period.
Mortality is higher in ESRD patients than in the age-matched
general population [12—14]. This may be related to comorbid
differences between ESRD patients and the general population
[15] and to treatment related factors such as blood pressure
control, HD dose, nutritional status, etc. [16, 17]. SMR1 showed
how many times Uruguayan ESRD patients die in comparison to
the national general population. During the first years of CHT in
Uruguay some elderly and complicated patients (who may also be
diagnosed with arteriosclerotic heart disease, peripheral vascular
disease, cerebral stroke, cirrhosis, or cancer malignancy) were not
referred by the internists. Afterwords, owing to the accumulated
experience and good results, more at risk patients were referred
and accepted. Therefore, comorbid conditions were probably
worse in the last years of this study. In spite of this, SMR1
decreased from 21 to 4. In our opinion this could be explained by
a better quality of treatment. As elucidated in the Methods
section, several treatment related technologies improved during
this period.
Mortality in ESRD patients disclosed strong geographical
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Year
differences. Lower values were reported by Japan and the EDTA
Registry. Gross mortality in Japan ranged from 8.8% in 1980 to
9.2% in 1988 [18]. In the EDTA Registry the death rate ranged
from 102 in 1980 to 111 deaths per 1000 patient-years in 1987 [19].
In 1986 in the USA mortality was 211.1 deaths per 1000 patient-
years and 211.9 in 1990 [12]. The Latin American Dialysis
Registry showed a gross mortality of 16.7% in 1991 [14].
To make an international comparision of mortality in ESRD
patients is difficult due to different methods of treatment and time
periods considered for analysis. The recent publication of mortal-
ity tables by age, race and renal disease by Wolfe et al [4] offers
the possibility to make a suitable comparision. The overal death
rate in USRDS 1987 to 1989 was 250.6 per 1,000 patient-years at
risk. Since 1985, the SDR2 values were lower than that number
(Fig. 5). This is difficult to explain. Countries with agressive
transplant policies may have increased mortality in chronic dial-
ysis programs because younger and healthier patients are selected
to receive transplants [20]. Considering that renal transplant
activity in Uruguay was lower, these factors could partially explain
Fig. 1. Annual changes in incidence • I) and
point prevalence at December 31 (. P) of ESRD
patients in Uruguay. I and P were expressed as the
number per million population.
0 1 2 3 4 5 6 7 8 9 10
Time, years since onset of ESRD
Fig. 2. Kaplan-Meier hemodialysis patient survival curves in non-diabetic
(non D) and diabetic (D) patients. Diabetic patients had a significantly
worse survival than non-diabetic patients.
Year
Fig. 3. Percentage of patients older than 65 years () and diabetics ()
among patients alive at Janua,y 1, from 1981 to 1991.
Year
Fig. 4. The ratio between the number of observed and expected deaths
(SMR1) among chronic hemodialysis patients during the period of 1981 to
1991, according to the age-matched general population in Uruguay. In 1981
chronic hemodialysis patients died 27 times more than general population
and in 1991 this ratio was 4. During the period, 717 patients died; expected
deaths were 102. Overall SMR1 was 717/102 = 7.
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Fig. 5. Overall mortality rate for the 1665
patients considered (selected using Woift et al
criteria [4]) was 119 death/1000 patient-years at
risk; in 1981 it was 236 decreasing to 79 in 1991
•). When the USA ESRD 1987 to 1989
mortality rate by age, race and diagnosis was
used as a standard, the standarized death rate
was 143 deaths/1000 patient-years, ranging from
516 in 1981 to 83 in 1991 ().
the mortality differences. Comorbid conditions upon entrance is
an accepted mortality factor [211. In our analysis the role of this
factor on the death rate differences was not considered. The
prescription for dialysis therapy and the reuse of dialyzers have
received increasing recognition as affecting overall program sur-
vival results. Shorter dialysis is associated with higher mortality
[22]. In Uruguay most patients have been dialyzed for 12 hours
per week since 1986. Dialysis time appears to be shorter in the
United States [23], and this could be another factor to explain the
mortality differences. It has been proposed that reuse could play
a role in the mortality differences among European, Japanese and
USA patient populations [24]. In fact, mortality is lower in Europe
where only 10% of centers reuse dialyzers and in Japan where
there is no reuse at all. In Uruguay, like in the USA, it is a
wide-spread practice, so the mortality difference could not stem
from reuse.
These overall results point out that, with suitable national
funding strategies, it is possible to properly undertake ESRD
treatment in developing countries. Efforts of the Uruguayan
Society of Nephrology to keep the national register updated has
allowed yearly knowledge of the incidence, prevalence and mor-
tality rates, and to directly improve treatment outcomes.
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